- Home
- / SAB Biotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
SAB Biotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$2.9
2024-10-29
Market Capitalization
$26.7 M
2024-10-29
Revenue
$1.3 M
FY, 2024
CreditSafe Score
?
Score changed on Jul 19, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 60.9M | 23.9M | 2.2M | 1.3M | ||
| General and administrative expense | 17.1M | 16.4M | 23.8M | 14.0M | 14.6M | |
| Operating expense total | 74.3M | 52.8M | 40.3M | 44.2M | 49.0M | |
| EBIT | (13.4M) | (28.9M) | (38.1M) | (42.9M) | (49.0M) | |
| EBIT margin, % | -22.0% | -121.0% | -1700.6% | -3244.9% | ||
| Interest income | 23.1K | 71.1K | 585.0K | 1.3M | 1.4M | |
| Interest expense | 294.5K | 301.6K | 315.3K | 374.0K | ||
| Pre tax profit | (17.1M) | (18.7M) | (42.2M) | 13.3M | ||
| Income tax expense | 25.6K | |||||
| Net Income | (9.0K) | (17.1M) | (18.7M) | (42.2M) | (34.1M) | 13.3M |
| EPS | (0.6) | (7.6) | (3.7) | (0.8) |